Diabetes Drug Linked to Higher Glaucoma Risk
Patients with diabetic macular edema may face increased ocular pressure risks after anti-VEGF therapy.
Updated on Oct. 12, 2026 in Diabetes
Live Poll
Do you trust that your doctor sufficiently monitors the long-term side effects of your prescribed treatments?
A retrospective study of 40,000 patients found that individuals treated with anti-VEGF agents for diabetic macular edema experienced a higher five-year incidence of glaucoma and ocular hypertension. These findings were presented at the EURETINA 2026 conference.
Why it matters
Understanding this association helps patients and clinicians better weigh the risks and benefits of long-term vision-preserving treatments. This research highlights the need for ongoing eye monitoring for those undergoing anti-VEGF therapy for diabetes-related complications.
A study analyzing data from over 40,000 patients used propensity score matching to compare those receiving anti-VEGF therapy to a control group over five years. Treated patients showed a hazard ratio of 2.8 for developing glaucoma or ocular hypertension, though the precise mechanism remains unclear.
The players
EURETINA
A professional medical society focused on advancing the study and treatment of retinal diseases.
The details
Researchers examined medical billing and diagnostic codes to determine the five-year risk profile for patients with diabetic macular edema. The study excluded individuals with pre-existing glaucoma, ocular hypertension, or those on long-term systemic corticosteroids to isolate the impact of the treatment. Anti-VEGF agents are commonly used to prevent vision loss, but this analysis indicates they may be associated with secondary ocular pressure complications in a significant subset of the population.
Timeline
The EURETINA 2026 conference took place in 2026.
Patient risk was observed over a duration of 5 years.
Health Landscape
This study follows a pattern of using the TriNetX US Collaborative network to perform large-scale retrospective analyses on population-level health outcomes. It adds important long-term safety context to the current standard of care for managing diabetic eye disease.
If you are currently receiving anti-VEGF treatments for diabetic macular edema, consider discussing regular eye-pressure screenings with your ophthalmologist. It is especially important to monitor for any new symptoms of vision change or eye discomfort throughout your treatment course.
The takeaway
Long-term anti-VEGF therapy is associated with a higher risk of ocular hypertension, suggesting that vigilance is required beyond the initial treatment phase. Always discuss your specific risk factors for glaucoma and any necessary monitoring schedules with your primary eye care provider.
Further reading
For more on managing eye health, see our latest guidance in the Diabetes section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that your doctor sufficiently monitors the long-term side effects of your prescribed treatments?
